S Kim - Department of Oncology, Asan Medical Centre

基本信息

浏览量：57

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 15 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

1254MO Safety and Anti-Tumour Activity of Zipalertinib in NSCLC Patients (pts) with EGFR Exon 20 Insertion (ex20ins) Mutations Who Received Prior Amivantamab

A. Passaro,H.A. Yu,D. Nguyen,V.H.F. Lee,R.A. Soo,S.H. Kim,H. Daga, D.S.W. Tan,S-W. Kim,O.J. Juan Vidal,Z. Piotrowska, E.K. Keeton, T. Liu, S. Li, J. Jones,G. Ruiter

Annals of Oncology (2024): S803-S804

引用0浏览0引用

60 CONTACT-01: Efficacy and Safety from a Phase III Study of Atezolizumab (atezo) + Cabozantinib (cabo) Vs Docetaxel (doc) Monotherapy in Patients (pts) with Metastatic NSCLC (mnsclc) Previously Treated with Checkpoint Inhibitors and Chemotherapy

J. Neal,N. Pavlakis,S-W. Kim,Y. Goto,S.M. Lim,G. Mountzios,E. Fountzilas,A. Mochalova,D.C.C. Christoph,A. Bearz,X. Quantin,R. Palmero,V. Antic, E. Chun,T. Rao Edubilli, Y-C. Lin,M. Huseni, C. Scheffold, P. Vervaet,T. Newsom-Davis

Journal of Thoracic Oncology（2023）

引用3浏览0引用

1549Tip DeLLphi-303: Phase Ib First-Line Combination Study of Tarlatamab, a DLL3-targeting Half-Life Extended Bispecific T-cell Engager (HLE BiTE®), with Carboplatin, Etoposide, and PD-L1 Inhibition in Extensive Stage Small Cell Lung Cancer (ES-SCLC)

S.M. Gadgeel, J. Al-Mondhiry,M-J. Ahn,S-W. Kim,L. Paz-Ares,H. Prenen,M. Boyer,J.G. Bustamante Alvarez,B. Solomon, S. Huang,M. Minocha, M. Kistler,N. Hashemi Sadraei

Annals of Oncology (2022): S1255-S1255

引用0浏览0引用

Caregiver Willingness to Give TPT to Children Living with Drug-Resistant TB Patients

V. Rouzier,M. Murrill,S. Kim,L. Naini,J. Shenje,E. Mitchell, M. Raesi,M. Lourens,A. Mendoza,F. Conradie,N. Suryavanshi, M. Hughes,S. Shah,G. Churchyard,S. Swindells,A. Hesseling,A. Gupta

The International Journal of Tuberculosis and Lung Disease（2022）

引用4浏览0WOS引用

DeLLphi-303: Phase Ib first-line combination study of tarlatamab, a DLL3-targeting half-life extended bispecific T-cell engager (HLE BiTE?), with carboplatin, etoposide, and PD-L1 inhibition in extensive stage small cell lung cancer (ES-SCLC)

S. M. Gadgeel, J. Al-Mondhiry,M-J. Ahn,S-W. Kim,L. Paz-Ares,H. Prenen,M. Boyer,J. G. Bustamante Alvarez,B. Solomon, S. Huang,M. Minocha, M. Kistler,N. Hashemi Sadraei

ANNALS OF ONCOLOGY（2022）

引用0浏览0引用

P47.08 A Phase II, Single-arm, Multicenter, Efficacy of 80 Mg Osimertinib in Patients with Leptomeningeal Metastases Associated with EGFR Mutated NSCLC

S. Park,J.S. Lee,S. Kim,H.T. Kim,K.H. Lee,D. Kim,M. Ahn

Journal of Thoracic Oncologyno. 10 (2021): S1099

引用0浏览0引用

A Phase II, Single-arm, Multicenter, Efficacy of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC

S. Park,J. S. Lee,S. Kim,H. T. Kim,K. H. Lee,D. Kim,M. Ahn

JOURNAL OF THORACIC ONCOLOGY（2021）

引用0浏览0引用

Osimertinib Plus Platinum–pemetrexed in Newly Diagnosed Epidermal Growth Factor Receptor Mutation-Positive Advanced/metastatic Non-Small-cell Lung Cancer: Safety Run-in Results from the FLAURA2 Study

D. Planchard,P. -H. Feng,N. Karaseva,S. -W. Kim,T. M. Kim,C. K. Lee,A. Poltoratskiy,N. Yanagitani,R. Marshall,X. Huang,P. Howarth,P. A. Janne, K. Kobayashi

ESMO Open（2021）

引用51浏览0WOS引用

Primary Results of ALESIA: A Randomised, Phase III, Open-Label Study of Alectinib Vs Crizotinib in Asian Patients with Treatment-Naïve ALK+ Advanced NSCLC

C. Zhou,Y. Lu,S-W. Kim,T. Reungwetwattana,J. Zhou, Y. Zhang,J. He,J. J. Yang,Y. Cheng, S. H. Lee,L. Bu,T. Xu,L. Yang,C. Wang,P. N. Morcos,E. Mitry, T. Liu, L. Zhang

Annals of Oncology（2018）

引用21浏览0WOS引用

Resource utilization for multidrug-resistant tuberculosis household contact investigations (A5300/I2003)

S Swindells,A Gupta,S Kim,M D Hughes, J Sanchez,V Mave,R Dawson,N Kumarasamy,K Comins,B Smith,R Rustomjee,L Naini,N S Shah,A Hesseling,G Churchyard

The international journal of tuberculosis and lung disease : the official journal of the Internation...（2018）

引用3浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn